Breaking Down Medley, Inc. Financial Health: Key Insights for Investors

Curious whether Medley, Inc. (4480.T) is a growth story worth your attention? The company delivered a robust top-line surge - ¥27,536 million in net sales for the nine months to Sept 30, 2025 (a 27.2% YoY increase) and ¥35,196 million TTM revenue (+31.95%), yet profitability is under pressure with operating profit down 31.7% to ¥1,611 million and net profit to owners plunging 52% to ¥1,114 million as investments in its HR PF and Medical PF (Q3 growth of 27% and 38% YoY, respectively) eat into margins; balance sheet dynamics show total debt of ¥18.3 billion versus cash of ¥13.5 billion (net debt ≈ ¥4.74 billion) and a debt-to-equity of 1.01 while liquidity remains adequate (current ratio 1.64, quick ratio 1.53, interest coverage 11.15) and free cash flow of ¥2.38 billion TTM; valuation signals include an estimated intrinsic value of ¥3,044.47 (≈35.9% upside from a ¥2,240 market price), trailing P/E 49.36, forward P/E 21.87 and EV/EBITDA 19.34, but investors should weigh a 53.5% downward revision to FY2025 net profit (now ¥1,300 million), rising liabilities (total liabilities ¥29.36 billion), and heavy investing cash outflows against ambitious mid-term targets of ¥100 billion sales and ¥20 billion EBITDA by FY2029 and strategic moves like U.S. expansion and a ¥3,000 million share repurchase authorization.

Medley, Inc. (4480.T) - Revenue Analysis

• Primary growth drivers:
  • Human Resources Platform (HR PF) - Q3 sales growth recovered to +27% YoY.
  • Medical Platform (Medical PF) - accelerated to +38% YoY in Q3.
• Profitability headwinds:
  • Operating profit down 31.7% in 9M due to increased investments and operating costs.
  • Ordinary profit declined 54.9% in 9M, reflecting both higher OPEX and cost of growth.
• Guidance and outlook:
  • Full‑year revenue forecast trimmed to ¥36,900 million, indicating a more cautious near‑term outlook despite strong mid‑year growth.

Medley, Inc. (4480.T) - Profitability Metrics

Medley, Inc. reported a meaningful deterioration in core profitability for the nine months ending September 30, 2025, driven by increased investments and operating costs in growth initiatives (HR PF and Medical PF).

• Operating profit (9M to Sep 30, 2025): ¥1,611 million (down 31.7% year-on-year)
• Net profit attributable to owners (9M to Sep 30, 2025): ¥1,114 million (down 52% year-on-year)
• Full-year 2025 net profit forecast: revised down 53.5% to ¥1,300 million
• Q3 EBITDA margin: 10%
• Nine-month EBITDA: ¥3,578 million (up 2.7% year-on-year)

• Primary drivers: increased investment into HR PF and Medical PF businesses, higher short-term operating costs to capture future growth.
• Offsetting factor: EBITDA growth and improved Q3 margin indicate some operational leverage despite margin compression at the operating and net levels.

Further context on the company and its strategy is available here: Medley, Inc.: History, Ownership, Mission, How It Works & Makes Money

Medley, Inc. (4480.T) - Debt vs. Equity Structure

• Leverage trend: Debt increased ~41.9% year‑over‑year (¥12.9B → ¥18.3B), raising financing risk if earnings or cash flow weaken.
• Liquidity buffer: ¥13.5B cash keeps net debt moderate (¥4.74B), improving short-term flexibility versus gross debt level.
• Capital mix: Debt-to-equity ~1.01 indicates roughly equal weighting of debt and equity; equity ratio decline to 37.8% reflects higher debt share.
• Balance sheet exposure: Debt-to-assets ~0.62 means 62% of assets are financed by liabilities; increases in liabilities merit monitoring for covenant or refinancing pressure.
• Key watch items: interest coverage, upcoming maturities, cash conversion, and changes to working capital that could affect ability to service higher debt.

Medley, Inc. (4480.T) - Liquidity and Solvency

• Current ratio: 1.64 - sufficient short-term assets to cover current liabilities.
• Quick ratio: 1.53 - strong immediate liquidity when inventory is excluded.
• Interest coverage ratio: 11.15 - robust ability to meet interest expenses from operating earnings.

• Cash buffer vs. liabilities: cash & short-term investments cover ~46% of total liabilities (¥13.52B / ¥29.36B).
• Cash generation: operating and free cash flow remain positive and closely aligned, suggesting efficient capex management.
• Debt service capacity: interest coverage of 11.15 provides a significant margin for interest obligations.

Medley, Inc. (4480.T) Valuation Analysis

• Intrinsic value (10/22/2025): ¥3,044.47 per share - implies a 35.9% upside versus market price of ¥2,240.00.
• Market capitalization: ¥68.28 billion; Enterprise value: ¥73.02 billion.

• High trailing P/E (49.36) signals that recent earnings are low relative to market price or that investors are pricing strong growth expectations into the stock.
• Forward P/E (21.87) is materially lower than trailing P/E, indicating expected earnings acceleration or analyst revisions improving near-term EPS.
• EV/EBITDA at 19.34 suggests the market is paying a premium for operating cash-flow generation relative to peers in healthcare/technology-adjacent sectors.
• P/S of 2.07 and P/B of 3.78 both indicate the stock trades above simple revenue and book baselines, consistent with growth/quality premium pricing.

• Relative to intrinsic value, the estimated 35.9% upside provides a margin for prospective returns if underlying assumptions hold.
• Premium multiples imply execution risk: growth miss or margin compression would pressure valuation quickly given high earnings multiple sensitivity.
• Enterprise value close to market cap (¥73.02B EV vs. ¥68.28B market cap) reflects modest net debt or adjustments-capital structure does not massively distort valuation metrics.

Medley, Inc. (4480.T) - Risk Factors

Medley, Inc. (4480.T) faces several material risks that investors should weigh carefully, driven by weaker profitability, higher leverage, large investing outflows and concentration in specific business lines.

• Sharp decline in operating profit and net profit attributable to owners in FY2025, undermining investor confidence and future profitability.
• Increase in total debt and a higher debt-to-equity ratio, raising concerns about financial leverage and the company's ability to service obligations.
• Full-year FY2025 net profit forecast revised downward by 53.5% to ¥1,300 million, signaling difficulty in meeting prior profitability targets.
• Equity ratio decreased to 37.8% from 44.7% at the previous year-end, indicating a greater reliance on debt financing.
• Substantial negative investing cash flow reflecting large capital deployment, which may not deliver anticipated returns.
• Concentration risk from reliance on HR PF and Medical PF segments exposes performance to sector-specific regulatory and competitive pressures.

• Profitability risk: With operating profit roughly halved in FY2025 and net profit forecasts slashed to ¥1,300 million, margin recovery depends on rapid cost control or outsized revenue growth.
• Leverage and solvency: Total debt rising to approximately ¥8.4 billion and a debt-to-equity near 1.2 materially reduce balance-sheet flexibility; equity ratio falling to 37.8% signals increased creditor exposure.
• Investment execution risk: ¥6.2 billion of negative investing cash flow implies large deployments-if these fail to generate projected returns, impairment and further write-down risk increases.
• Sector concentration: Heavy dependence on HR PF and Medical PF means regulatory changes (e.g., healthcare reimbursement policy, labor regulations) or intensified competition could disproportionately impact revenues.

For context on investor composition and recent buying patterns related to these risks, see: Exploring Medley, Inc. Investor Profile: Who's Buying and Why?

Medley, Inc. (4480.T) Growth Opportunities

• Mid-term targets: ¥100,000 million sales and ¥20,000 million EBITDA by FY2029, implying a target EBITDA margin of ~20% if targets are achieved.
• Share repurchase program: authorization to repurchase up to 1.5 million shares for up to ¥3,000 million, signaling management confidence and potential EPS accretion.

• HR PF (Human Resources Platform): Sales growth recovered to 27% year-on-year in Q3, indicating renewed demand and an improving top-line trajectory in staffing/HR-related services.
• Medical PF (Medical Platform): Growth accelerated to 38% year-on-year in Q3, driven by product adoption and platform monetization.
• Brand renewal & system efficiency: Ongoing brand refresh and back-office / platform efficiency projects in Medical PF present an opportunity to raise conversion rates, lower unit costs and capture market share.
• U.S. expansion: Launch and scaling of the medical platform business in the U.S. offer revenue diversification and access to a larger addressable market; successful localization and regulatory execution will be key.
• M&A strategy: Targeted mergers and acquisitions aimed at bolstering platform capabilities and accelerating user acquisition/commercial scale.

• Execution vs. targets: Achieving ¥100B/¥20B by FY2029 requires sustained high-single/low-double-digit organic growth plus accretive M&A.
• Margin leverage: System efficiency and scaling in Medical PF could materially improve EBITDA margin toward the mid-term target if unit economics hold.
• Geographic risk/reward: U.S. expansion offers large upside but entails regulatory, competitive and marketing investments that may compress near-term margins.
• Capital returns: The ¥3,000M repurchase program reduces share count and demonstrates management conviction while preserving flexibility for M&A.